Background Little is known about the long-term outcome of implantable cardioverter defibrillator (ICD) therapy in survivors of out-of-hospital cardiac arrest (OHCA).
atients with out-of-hospital cardiac arrest (OHCA) still have an unsatisfactory outcome, not only in the acute period but also in the chronic period, and favorable neurological recovery from OHCA is still limited to exceptional individuals. [1] [2] [3] [4] Detailed information on community-based education for out-of-hospital basic life support, a sophisticated emergency-call system and an automated external defibrillator used by non-medical staff has been provided to improve the acute-phase prognosis of OHCA patients. 5 Furthermore, cardiopulmonary bypass, mild hypothermia and coronary intervention have been proposed as promising therapeutic options to improve inhospital prognosis of OHCA patients. [6] [7] [8] [9] [10] [11] However, there is little information on the long-term prognosis of survivors of OHCA. A guideline for treatment and a follow-up program must be established to prevent the recurrence of lethal arrhythmias, including ventricular fibrillation (VF) and ventricular tachycardia (VT).
The use of an implantable cardioverter defibrillator (ICD) has been recommended for preventing cardiac arrest by effective defibrillation and anti-tachycardia overdrive pacing in high-risk patients with or without organic heart disease. [12] [13] [14] According to recently published American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, 15 a patient with (1) cardiac arrest by VF or VT not due to a transient or reversible cause, (2) spontaneous sustained VT in association with structural heart disease, (3) hemodynamically significant sustained VT or VF induced in an electrophysiological study (EPS) and (4) reduced left ventricular (LV) function should be treated with an ICD. Therefore, an ICD should be used to prevent the recurrence of lethal arrhythmia in survivors of OHCA with favorable neurological recovery. However, there is limited information [16] [17] [18] on how often and when lethal ventricular arrhythmia might occur and whether an ICD can prevent recurrence of cardiac arrest in survivors of OHCA during the long-term.
The aim of this study was to determine whether ICD therapy for survivors of OHCA with favorable neurological recovery can prevent recurrence of cardiac arrest.
Methods

Subjects
From July 1999 to October 2003, a total of 23 consecutive adult patients with cardiac-origin OHCA (OHCA group) (14 males, 9 females; mean age, 49±16 years; range 15-73 years) were selected for this study according to the following criteria: (1) de novo cardiac-origin OHCA with definite diagnosis (excluding acute coronary syndrome or acute myocarditis), (2) documented VF (n=21) or polymor-phic VT (n=2) on the first ECG record at the scene of OHCA, (3) favorable neurological recovery (good recovery or mild disability on Glasgow outcome scale) on the 30th day after onset, and (4) treated with an ICD for preventing recurrence of lethal arrhythmia in the sub-acute phase. We excluded patients with unfavorable recovery because they did not receive an ICD and their precise clinical follow-up might be difficult. OHCA patients in whom lethal arrhythmia was induced by pro-arrhythmic agents were also excluded. OHCA patients included in this study were 17% of total cardiac-origin OHCA patients with definite diagnosis (n=132). Bystander cardiopulmonary resuscitation was performed in 23% of the subjects. The mean time intervals from onset to emergency call and from emergency call to arrival of an emergency life-saving technician were 4.1 and 9.1 min, respectively. The rate of return of spontaneous circulation achieved using on-site counter shock was 7%. Cardiopulmonary bypass was performed in 32% of the OHCA patients. Thirty-five patients without OHCA who received an ICD in the same period were included as control subjects (non-OHCA group).
Diagnosis of Cardiovascular Disease
Diagnosis of cardiovascular disease was determined by direct interviews with the patients and their families and by retrospective examination of medical records after receiving written informed consent. Standard laboratory examinations, chest X-ray, computed tomography, echocardiography, and cardiac catheterization (including myocardial biopsy in cases of suspected cardiomyopathy) were performed. VF without organic heart disease was defined as idiopathic.
EPS and ICD Implantation
Clinical arrhythmia was basically defined as the ventricular tachyarrhythmias that caused OHCA or the most severe documented ventricular tachyarrhythmias before ICD implantation. Spontaneous arrhythmia was defined as the most severe ventricular arrhythmia that occurred during the period from the day after OHCA to the day of ICD implantation (which was not evaluated in the non-OHCA group). VF or VT in the EPS was induced by triple-paired pacing (minimal coupling interval, 180 ms) and by train pacing from several right ventricular sites, including the apex and outflow. VT was defined as 3 or more consecutive extrasystoles, and VT that continued for more than 30 s was considered as sustained VT. VF was defined as ventricular tachyarrhythmia in which the heart rate was more than 250 beats/min with syncope. New York Heart Association (NYHA) functional class at hospital discharge and LV ejection fraction on an echocardiogram were also examined.
Implantation of the defibrillator (Micro Jewel II, GEM, and GEM II, Medtronics, Kawasaki, Japan or VENTAK MINI IV, Guidant, Tokyo, Japan) was performed in accordance with the ACC/AHA guidelines. 15 The ACC/AHA classifications of recommendation for implantation were class I in all patients in the OHCA group and in 29 patients in the non-OHCA group, and class IIb in 6 patients in the non-OHCA group. The device was implanted into the subclavicular position with transvenous leads and in 36 patients we selected dual-chamber pacing mode because of atrioventricular block or atrial fibrillation.
Follow-up
In-hospital outcome was determined by several medical staff on the 30th hospital day after onset of OHCA using the Glasgow outcome scale: good recovery, moderate disability, severe disability, vegetative state, and death. In this study patients with good recovery or moderate disability were defined as those having favorable neurological recovery. After discharge, all patients in the OHCA and non-OHCA groups were followed at a pacemaker clinic every 3 months for 24.4±11.9 months (range, 7-53 months). Cardiac events were defined as cardiac death, recurrent lethal arrhythmia with ICD discharge, and congestive heart failure requiring hospitalization. Programming of the ICD on a telemeter record was classified into defibrillation, cardioversion, or anti-tachycardia pacing. The types of ventricular arrhythmias treated by the ICD were also analyzed.
Statistical Analysis
All numeric data are expressed as means ± SD. The differences between 2 independent variables or incidences in 2 groups were compared by Student's unpaired t-test or by the chi-square test. Kaplan-Meier life table analysis was used for determining group differences in cardiac events. P<0.05 was considered to be statistically significant.
Results
Clinical Background and Underlying Heart Diseases
As shown in Table 1 , the OHCA (n=23) and non-OHCA groups (n=35) had the same clinical background with regard to age, gender, and underlying heart disease. The proportion of patients without organic heart disease was 22% in the OHCA group (long QT syndrome [n=1], idiopathic VF [n=4]) and 23% in the non-OHCA group (Brugada syndrome [n=4], polymorphic VT [n=3], long QT syndrome [n=1]). All patients with Brugada syndrome had a history of syncope. Polymorphic VT patients without OHCA included 2 with a short-coupled variant of Torsade de pointes and 1 with catecholaminergic polymorphic VT. No significant differences between the OHCA and non-OHCA groups were found for the indices of cardiac function: NYHA functional class, LV ejection fraction, and LV diastolic dimension on echocardiogram. Anti-arrhythmic agents were administered to 72% of the patients in the OHCA group and to 83% of the patients in the non-OHCA group (amiodarone to 35% of the patients in the OHCA group vs 29% of the patients in the non-OHCA group).
Clinical and Induced Ventricular Arrhythmia
Electrophysiological data and data on clinical arrhythmia are shown in Table 2 . In the OHCA group, all patients had clinical sustained VT or VF, whereas in the non-OHCA group, 25 had clinical sustained VT and 7 had clinical non-sustained VT with syncope. Although 3 patients with Brugada syndrome had no documented clinical or induced VT or VF, they were treated with an ICD because they had a history of syncope of undetermined cause. Spontaneous arrhythmia was confirmed in 6 OHCA patients (26%). EPS was performed in 14 (61%) of the patients in the OHCA group and in 28 (80%) of the patients in the non-OHCA group. In the non-OHCA group, all patients with clinical sustained VT had organic heart disease. Sustained VT or VF was induced in 79% of the non-OHCA patients during the EPS but in only 36% of the OHCA patients (p<0.05). VF was induced in only 7% of the OHCA patients. The induction rate of VT or VF in EPS in OHCA patients with organic heart disease was 50%, whereas the rate in non-OHCA patients was 86%. Underlying heart disease did not influence the induction rate of ventricular arrhythmia in EPS.
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Cardiac Events
During a mean follow-up period of 24.4±11.9 months, cardiac events occurred in 30% (7/23) of the OHCA patients and in 49% (17/35) of the non-OHCA patients. Patients in the OHCA group had almost the same incidence of ICD discharge as the patients in the non-OHCA group. In the OHCA group, ICD discharge ratios in patients with and without induced sustained VT or VF during the EPS were 60% (3/5) and 22% (2/9), respectively, and 32% (7/22) and 67% (4/6), respectively, in the non-OHCA group (NS). The VT rates with ICD discharge in the OHCA and non-OHCA patients were 184±25 beats/min and 172±37 beats/min, respectively. The rate of recurrence of VF in the OHCA patients was high (13%). Nine patients were admitted for exacerbation of heart failure and 1 patient (4%) in the OHCA group and in 3 (9%) in the non-OHCA group died of cardiac death. Kaplan -Meier analysis revealed that the cumulative cardiac event-free rates in the 2 groups were the same (Fig 1) . ICD discharge ratios in patients with reduced LV ejection fraction (<30%) on echocardiography were 50% (1/2) in the OHCA group and 40% (2/5) in the non-OHCA group. ICD discharge ratios in patients with organic heart disease were 28% (5/18) in the OHCA group and 37% (10/27) in the non-OHCA group. Frequent ICD discharge was observed in 2 (50%) of 4 idiopathic VF patients in the OHCA group and in 2 (67%) of 3 polymorphic VT patients in the non-OHCA group.
Discussion
We investigated the long-term outcome of ICD therapy for patients (excluding those with acute coronary syndrome and acute myocarditis) who were successfully resuscitated after OHCA (OHCA group) compared with that for patients without OHCA (non-OHCA group). Our results show that (1) the incidence of ICD discharge was almost same in the 2 groups and was very high (30% in the OHCA group, 40% in the non-OHCA group), (2) the rate of recurrence of VF in the OHCA patients was high (13%), and it was difficult to estimate the rate by induced arrhythmia, and (3) the ICD implantation prevented recurrence of OHCA.
Long-Term Prognosis
Several recent multicenter trials, such as AVID, 12 have revealed that ICD therapy for OHCA patients can reduce the risk of cardiac death, especially in those cases that are complicated with heart failure. In this study, ICD discharge occurred in 30% of the OHCA patients, 28% of whom had organic heart disease. ICD discharge occurred in half of the OHCA patients with reduced LV function. Moreover, patients with idiopathic VF or polymorphic VT also had frequent ICD discharge. Therefore, an ICD can prevent the recurrence of lethal arrhythmia in survivors of OHCA, especially those with LV dysfunction, idiopathic VF, or polymorphic VT.
Evaluation of Arrhythmogenecity in Survivors of OHCA
Recent ACC/AHA guidelines simply indicate that ICD therapy should be considered for a patient with cardiac arrest by VF or VT not due to a transient or reversible cause. However, there is limited information on how often and when lethal ventricular arrhythmia might occur and whether an ICD can prevent recurrence of OHCA in the long term. In this study, the incidence of recurrence of lethal arrhythmia was very high in survivors of OHCA (30%, VT in 4 and VF in 3 cases). Ruppel et al also reported that the incidence of recurrence of lethal arrhythmia in survivors of cardiac arrest was high (33%, VT in 11 and VF in 2 cases). 19 An EPS is considered useful in the evaluation and treatment of patients with ventricular arrhythmia. Ruskin et al reported that EPS-induced ventricular arrhythmia occurred in 25/31 (81%) of OHCA survivors and that the EPS might be useful for determining drug efficacy and thus preventing sudden cardiac arrest. 20 In the present study, many of the non-OHCA patients had monomorphic sustained VT, and many of the OHCA patients had VF. We consider that differences in the arrhythmic modality may have affected the induction rate of VT or VF during the EPS; however, only 61% of the OHCA patients underwent an EPS and we could not confirm its usefulness for predicting outcome in survivors of OHCA.
We conclude that an ICD should be implanted in survivors of OHCA with favorable neurological recovery to prevent recurrence of lethal arrhythmia, not only in those with induced lethal arrhythmia in the EPS but also for those without induced arrhythmia.
Study Limitation
The data come from a single cardiovascular center with a small number of patients and the study was not a doubleblind randomized trial. However, considering the ethical aspects of treating an OHCA, it would be difficult to carry out a double-blind study.
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